Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
Reads0
Chats0
TLDR
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.Abstract:
Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods Two randomized, double-blind, placebo-controlled studies — the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively) — evaluated the efficacy of infliximab for induction and maintenance therapy in adults with ulcerative colitis. In each study, 364 patients with moderate-to-severe active ulcerative colitis despite treatment with concurrent medications received placebo or infliximab (5 mg or 10 mg per kilogram of body weight) intravenously at weeks 0, 2, and 6 and then every eight weeks through week 46 (in ACT 1) or week 22 (in ACT 2). Patients were followed for 54 weeks in ACT 1 and 30 weeks in ACT 2. Results In ACT 1, 69 percent of patients who received 5 mg of infliximab and 61 percent of those who received 10 mg had a clinical response at week 8, as compared with 37 percent of those who received placebo (P<0...read more
Citations
More filters
Journal ArticleDOI
A microbial symbiosis factor prevents intestinal inflammatory disease
TL;DR: It is reported here that the prominent human symbiont Bacteroides fragilis protects animals from experimental colitis induced by Helicobacter hepaticus and that molecules of the bacterial microbiota can mediate the critical balance between health and disease.
Journal ArticleDOI
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G. Feagan,Paul Rutgeerts,Bruce E. Sands,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,William J. Sandborn,Gert Van Assche,Jeffrey Axler,Hyo-Jong Kim,Silvio Danese,I. Fox,Catherine Milch,Serap Sankoh,Tim Wyant,Jingcan Xu,Asit Parikh +16 more
TL;DR: Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.
Journal ArticleDOI
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.
Asher Kornbluth,David B. Sachar +1 more
TL;DR: Guidelines for clinical practice are aimed to indicate preferred approaches to medical problems as established by scientifically valid research, and are applicable to all physicians who address the subject regardless of specialty training or interests.
Journal ArticleDOI
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
TL;DR: The current diagnostic approach, their pathology, natural course, and common complications, the assessment of disease activity, extraintestinal manifestations, and medical and surgical management are discussed, and diagnostic and therapeutic algorithms are provided.
Journal ArticleDOI
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
TL;DR: The biology of T NF and related family members are discussed in the context of the potential mechanisms of action of TNF antagonists in a variety of immune-mediated inflammatory diseases.
References
More filters
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Stephan R. Targan,Stephen B. Hanauer,S. J. H. Van Deventer,Lloyd Mayer,Daniel H. Present,T. Braakman,K. L. Dewoody,T. F. Schaible,Paul Rutgeerts +8 more
TL;DR: A 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 patients with moderate-to-severe Crohn's disease that was resistant to treatment, finding clinical response, the primary end point, was a reduction of 70 or more points in the score on theCrohn's Disease Activity Index at four weeks.
Journal ArticleDOI
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Daniel H. Present,Paul Rutgeerts,Stephan R. Targan,Stephen B. Hanauer,Lloyd Mayer,R. A. van Hogezand,Daniel K. Podolsky,Bruce E. Sands,T. Braakman,K. L. Dewoody,Th.F. Schaible,S. J. H. Van Deventer +11 more
TL;DR: Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease and the most common adverse events for patients treated with infliximab were headache, abscess, upper respiratory tract infection, and fatigue.
Journal ArticleDOI
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
TL;DR: It is concluded that oral 5-ASA administered in a dosage of 4.8 g per day is effective therapy, at least in the short term, for mildly to moderately active ulcerative colitis.
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Related Papers (5)
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more